Wockhardt Group, a research based Global Pharmaceutical and Biotech major, has set up its first facility in Middle East, catering to the global market through its Dubai arm.
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt inaugurated a ‘state-of-the-art’ manufacturing facility for the production and packaging of sterile dry powder injection in Dubai.
On approval of the new drug by the US FDA, the manufacturing facility will be commissioned for commercial production.
During the inauguration of the new facility, Dr. Habil Khorakiwala, Founder Chairman of Wockhardt said: “Wockhardt is poised for a quantum leap into the future.
“It is a future of dynamic changes, exciting possibilities and endless potential to further its goal of ‘Life Wins’ and Wockhardt is committed to shaping this future.
“With Wockhardt’s commitment to R&D, we have 5 breakthrough New Chemical Entities (NCEs) that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA.
“With the new facility in Middle East, we aim to focus on our commitment in developing NCEs to fight the health issues faced.”
Read more: DP World to Expand JAFZA